Citigroup Lowers Abbott Laboratories (NYSE:ABT) Price Target to $119.00

Abbott Laboratories (NYSE:ABT – Free Report) had its target price lowered by Citigroup from $128.00 to $119.00 in a research report released on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the healthcare product maker’s stock. Several other equities analysts also recently issued reports on ABT. Barclays decreased their price objective […]

Leave a Reply

Your email address will not be published.

Previous post Amalgamated Financial (NASDAQ:AMAL) versus Iowa First Bancshares (OTCMKTS:IOFB) Head-To-Head Contrast
Next post CAE (TSE:CAE) Downgraded to Hold at Canaccord Genuity Group